Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | PRKACA | P17612 | 1/20 | 0.65 |
| ▸ | FLT1 | P17948 | 1/20 | 0.65 |
| ▸ | LTK | P29376 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564437 | 0.81 | CDK9 (0.61) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL8860392 | 0.80 | GSK3A (0.72) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL3570573 | 0.79 | JAK2 (0.70) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL404434 | 0.79 | CHEK1 (1.00) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL8821144 | 0.79 | CHEK1 (0.70) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL12246135 | 0.77 | CHEK1 (0.53) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL439473 | 0.77 | HAVCR2 (0.48) | KDM4ECA12CA9KIF11 | |
| SCHEMBL463399 | 0.76 | HAVCR2 (0.67) | XDHKIF11 | |
| SCHEMBL8821127 | 0.76 | GSK3A (0.65) | CHEK1AURKADAPK3JAK2MAP4K4 | |
| SCHEMBL8821146 | 0.76 | GSK3B (0.65) | CHEK1AURKADAPK3JAK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-5631261-A | CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0673377-B1 | NEW TRIAZOLOQUINAZOLINES, THEIR PRODUCTION AND THEIR USE | BASF AG (DE) | 1997-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CHEK1 2106/4885AURKA 2527/4885DAPK3 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.